Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes

NCT00121992 is registered in ClinicalTrials.gov with Spanish Breast Cancer Research Group as lead sponsor.

NCT NCT00121992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Comparing Docetaxel, Doxorubicin and Cyclophosphamide (TAC) vs 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of High Risk Operable Breast Cancer Patients With Negative Axillary Lymph Nodes
Lead sponsor
Spanish Breast Cancer Research Group
Phase
Phase 3
Overall status
Completed
Start date
July 31, 1999
Completion date
March 6, 2013
Enrollment
1,060 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms